Teva Pharmaceutical Industries Limited Stock News

Teva Pharmaceutical Industries Limited (TEVA) Presents at J.P. Morgan 42nd Annual Global Healthcare Conference (Transcript)

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2023 financial resul

Small cap and mid cap biotech and speculative pharma stocks have a more constructive outlook heading into 2024, relative to previous years, but the idiosyncratic nature of the space continues to put a

Corcept Therapeutics shares fell by more than a quarter on Tuesday morning after a court found against it in a patent infringement lawsuit filed against Teva Pharmaceuticals. A US District Court said

Corcept Therapeutics Inc. shares CORT, -1.22% dropped 32% premarket on Tuesday after a federal court in New Jersey on Friday ruled against the drugmaker in its patent infringement lawsuit against Teva

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 42nd Annual J.P. Morgan

Jared Holz, Mizuho healthcare sector specialist, joins 'The Exchange' to discuss the 2024 outlook for health care, which stocks to buy in the new year, and more.

Indivior PLC (LSE:INDV), a company specialising in addiction treatment, has settled a legal dispute with Actavis, a part of Teva Pharmaceuticals. The disagreement was about Actavis's plan to make a ge

I am upgrading Teva Pharmaceutical to "Buy" for 2024, buoyed by opioid litigation resolution and promising drugs like TEV'574. Strong Q3 2023 performance, marked by revenue growth in Austedo, Ajovy, a

Generic and specialty pharmaceutical company Teva Pharmaceutical Industries Ltd. NYSE: TEVA stock has underperformed for nearly a decade.

Teva Pharmaceutical Industries (NASDAQ:TEVA) Ltd is uniquely positioned to undergo a significant transition to a more brand focused company that should drive outperformance of its stock price, accordi

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Evercore ISI HealthCONx

As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results. Regardless of sector or industry, every earnings sea

TEVA reports decent third-quarter results. The company raises its revenue guidance for 2023 for the second time this year while keeping the EPS range intact.

Teva Pharmaceutical Industries (NYSE:TEVA ) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Ran Meir - Senior Vice President, Investor Relations Richard Francis - Pre